Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dongsung, Herdeis, Lorenz, Rudolph, Dorothea, Zhao, Yulei, Böttcher, Jark, Vides, Alberto, Ayala-Santos, Carlos I., Pourfarjam, Yasin, Cuevas-Navarro, Antonio, Xue, Jenny Y., Mantoulidis, Andreas, Bröker, Joachim, Wunberg, Tobias, Schaaf, Otmar, Popow, Johannes, Wolkerstorfer, Bernhard, Kropatsch, Katrin Gabriele, Qu, Rui, de Stanchina, Elisa, Sang, Ben, Li, Chuanchuan, McConnell, Darryl B., Kraut, Norbert, Lito, Piro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322706/
https://www.ncbi.nlm.nih.gov/pubmed/37258666
http://dx.doi.org/10.1038/s41586-023-06123-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322706/
https://www.ncbi.nlm.nih.gov/pubmed/37258666
http://dx.doi.org/10.1038/s41586-023-06123-3

Ejemplares similares